Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Status Completed

Clinical Trial Summary

This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to efzofitimod (N=8) or placebo matched to efzofitimod (N=4).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03824392
Study type	Interventional
Source	aTyr Pharma, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 29, 2019
Completion date	June 29, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04064242` - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	Phase 2
Terminated	`NCT00262132` - Mycophenolate for Pulmonary Sarcoidosis	Phase 3
Recruiting	`NCT05415137` - Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis	Phase 3
Recruiting	`NCT00001532` - Role of Genetic Factors in the Development of Lung Disease
Completed	`NCT04318392` - Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Active, not recruiting	`NCT03755245` - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis	N/A
Completed	`NCT01587001` - The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis	N/A
Recruiting	`NCT05890729` - A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis	Phase 1/Phase 2
Recruiting	`NCT02824419` - Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis	Phase 2/Phase 3
Recruiting	`NCT06205121` - Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis	Phase 2
Completed	`NCT02200146` - Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).	Phase 3
Terminated	`NCT01732211` - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis	Phase 2
Enrolling by invitation	`NCT06169397` - An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis	Phase 2
Active, not recruiting	`NCT05368883` - Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis	N/A
Not yet recruiting	`NCT05247554` - Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis	Phase 3
Completed	`NCT03599414` - CASPA: CArdiac Sarcoidosis in PApworth
Recruiting	`NCT02188017` - Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)	Phase 4
Recruiting	`NCT06113991` - Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Completed	`NCT01169038` - Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis	Phase 1
Completed	`NCT00701207` - Study of Nicotine Patches in Patients With Sarcoidosis	Early Phase 1